Abstract: Processes for reducing the amount of a gaseous iodide-containing impurity present in a recycle gas stream used in the production of ethylene oxide, in particular an alkyl iodide impurity, are provided. Processes for producing ethylene oxide, ethylene carbonate and/or ethylene glycol, and associated reaction systems are similarly provided.

Abstract: The present disclosure provides processes for the production of 2-5-furandicarboxylic acid (FDCA) and intermediates thereof by the chemocatalytic conversion of a furanic oxidation substrate. The present disclosure further provides processes for preparing derivatives of FDCA and FDCA-based polymers. In addition, the present disclosure provides crystalline preparations of FDCA, as well as processes for making the same.

Abstract: A method for the reduction organic molecules comprising a Ruthenium-Triphosphine complex with aromatic ligands at the phosphors which are ortho or meta substituted.

Abstract: Nitroalkene non-steroidal anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of treating inflammation related conditions.

Abstract: In a process for the epoxidation of an olefin by continuously reacting the olefin with hydrogen peroxide in a methanol solvent on a fixed bed epoxidation catalyst comprising a titanium zeolite, the hydrogen peroxide is used as an aqueous hydrogen peroxide solution made by an anthraquinone process, the aqueous hydrogen peroxide solution is mixed with methanol to give a feed mixture and this feed mixture is filtered before being contacted with the fixed bed epoxidation catalyst.

Abstract: In a process for the epoxidation of propene, comprising the steps of reacting propene with hydrogen peroxide, separating propene oxide and a recovered propene stream from the reaction mixture, separating propane from all or a part of the recovered propene stream in a C3 splitter column, and passing the overhead product stream of the C3 splitter column to the epoxidation step, a propane starting material with a propane fraction of from 0.002 to 0.10 is used, the epoxidation is operated to provide a propane fraction in the reaction mixture of from 0.05 to 0.20 and the C3 splitter column is operated to provide an overhead product stream which comprises a propane fraction of at least 0.04 in order to reduce the size and the energy consumption of the C3 splitter column.

Abstract: Provided herein is a process for preparing furan-2,5-dicarboxylic acid. The process includes the following steps: (A-1) preparing a starting mixture comprising one, two or more carbohydrate compounds selected from the group consisting of: hexoses, oligosaccharides comprising hexose units, and polysaccharides including hexose units, and as a solvent or as a co-solvent for the carbohydrate compounds an amount of one or more carboxylic acid esters of a formula (II) and (A-2) subjecting the starting mixture to reaction conditions so that at least one of the one, two or more carbohydrate compounds reacts, and a fraction of the amount of one or more carboxylic acid esters of formula (II) is hydrolyzed, resulting in a mixture including 5-(hydroxymethyl)furfural and/or the one or more HMF esters of a formula (I), one or more carboxylic acids of a formula (III) and a remaining fraction of the amount of one or more carboxylic acid esters of formula (II).

Abstract: The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).

Abstract: Disclosed is simple, novel, scalable and environment friendly process for the preparation of enantiopure 3-amino tetrahydrofuran and its salts.

Abstract: Disclosed is a process to produce a purified vapor comprising dialkyl-furan-2,5-dicarboxylate (DAFD). Furan-2,5-dicarboxylic acid (FDCA) and an alcohol in an esterification zone to generate a crude diester stream containing dialkyl furan dicarboxylate (DAFD), unreacted alcohol, 5-(alkoxycarbonyl)furan-2-carboxylic acid (ACFC), and alkyl furan-2-carboxylate (AFC). The esterification zone comprises at least one reactor that has been previously used in an DMT process.

Abstract: The invention relates to a novel process for the conversion of a feedstock comprising at least one sugar to 5-hydroxymethylfurfural, in which said feedstock is contacted with one or more catalysts of the family of the homogeneous sulphonic acids in the presence of at least one aprotic polar solvent, used alone or in a mixture, at a temperature comprised between 30° C. and 200° C., and at a pressure comprised between 0.

Abstract: The current invention is directed to a class of compounds that inhibit the function of Thymidylate synthase. Thymidylate synthase inhibition was noted to result in inhibition of tumor cell grow and killing of tumor cells. Thymidylate synthase inhibition is, thus, useful for treatment of various types of cancers, including but not limited to, acute lymphoblatic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute monocytic leukemia (AMOL), hairy cell leukemia, large cell immunoblastic lymphoma, plasmacytoma, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, brain cancer, lung cancer, central nervous system (CNS) cancer, melanoma, renal cancer, prostate cancer, colon cancer, ovarian cancer and breast cancer. The compounds disclosed herein can be used alone or in combination with other cancer treatment regimens (e.g.

Abstract: The present invention relates to a compositions for and methods for cancer treatment, for example, hematopoietic cancers (e.g. B-cell Lymphoma). In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more of the disclosed compounds and, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with the disclosed compounds. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.

Abstract: The present invention provides an improved process for the preparation of Apremilast using novel intermediates. The present invention also relates to the novel crystalline polymorphic form of Apremilast.

Abstract: Provided herein are methods of producing halomethylfuroic and acyloxymethylfuroic acid and ester compounds from furfural starting compounds. For example, 5-chloromethyl-2-furoic acid may be produced from 5-chloromethylfurfural, in the presence of various oxidants. Salts of the furoic acids may also be produced.

Abstract: The present invention relates to a method for the catalytic synthesis of lactide from lactic acid. The method relates to the synthesis of lactide from lactic acid under the catalysis of a zinc oxide nanoparticle aqueous dispersion as a catalyst. The present invention has four technical characteristics: I. the zinc oxide nanoparticle aqueous dispersion catalyst has a sufficient surface area, and the size of nanoparticles is merely 30-40 nm, providing a sufficient contact area between the substrate (lactic acid) and the catalyst; II. the new catalyst has a milder catalytic effect on polymerization, allowing the molecular weight distribution of a prepolymer within a range of 400-1500 g/mol, which is advantageous for depolymerization to proceed; III. the new catalyst is stable, thus avoiding oxidation or carbonization in a high temperature reaction; and IV. the new catalyst has a low toxicity and a small threat to human health.

Abstract: A process for preparing furan-2,5-dicarboxylic acid is disclosed. The process includes the following steps: preparing or providing a starting mixture including 5-(hydroxy-methyl)furfural (HMF), 5,5?-[oxy-bis(methylene)]bis-2-furfural (di-HMF), and water; subjecting said starting mixture to oxidation conditions in the presence of an oxygen-containing gas and a catalytically effective amount of a heterogeneous catalyst including one or more noble metals on a support so that both HMF and di-HMF react to give furane-2,5-dicarboxylic acid in a product mixture also including water and oxidation by-products. The use of a catalyst is also disclosed, the catalyst including one or more noble metals on a support as an heterogeneous oxidation catalyst for catalyzing in an aqueous starting mixture the reaction of both HMF and di-HMF to furane-2,5-dicarboxylic acid.

Abstract: The invention provides a one pot method for generating propylene oxide, the method having the steps of contacting propane with catalyst clusters no greater than 30 atoms in the presence of oxygen for a time sufficient to directly convert the propane to the propylene oxide. The invented method eliminates the generation of intermediate compounds or intermediate reaction steps.

Abstract: Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.

Abstract: Cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.